Our study provides evidence that LRRFIP1 may play a pivotal role in the progression of pancreatic cancer, and it may be a potential biomarker and therapeutic target for pancreatic cancer. This evidence concerns the gene LRRFIP1 and familial pancreatic carcinoma.